Compare Amylx Pharmaceuticals Inc (AMLX) vs Ecopetrol SA (EC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Ecopetrol SA — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Ecopetrol SA trades at $17.01 (market cap $34.97B). The key difference: Ecopetrol SA is far larger — about 13.8× Amylx Pharmaceuticals Inc's market cap, and Ecopetrol SA pays a 3.81% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | EC | |
|---|---|---|
Market Cap | $2.53B | $34.97B |
Sector | Health | Energy |
52-Week High | $24.19 | $17.40 |
52-Week Low | $7.82 | $8.56 |
Enterprise Value | $2.28B | $65.28B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Ecopetrol (EC) trades at $16.78, down 3.56% on the day, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators are neutral. Fundamentally, revenue and net income have declined from 2022 peaks, though Q2 2026 earnings beat expectations. Recent news includes a cybersecurity incident and expansion efforts in Brazil, adding to volatility. Valuation ratios like P/E of 11.11 and P/S of 0.97 suggest potential undervaluation relative to historical metrics.
The outlook for EC is cautious; analyst consensus is mixed with a $15 price target below the current price. Risks include declining revenue trends, high debt levels, and operational disruptions from recent cyber threats. Opportunities lie in cost management and strategic acquisitions, but investor sentiment remains divided. The stock's near-term performance hinges on execution stability and energy market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →
